FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294131894> ?p ?o ?g. }

• W4294131894 abstract "Use of kinase inhibitors such as dasatinib and imatinib might increase the risk of opportunistic infections, especially Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections. However, the effect of sorafenib on EBV and CMV infections remains unclear. The aim of this study was to investigate the effect of sorafenib maintenance post-transplantation on the incidence and mortality of EBV and CMV infections in patients with FLT3-ITD acute myeloid leukemia.This was a follow-up of our randomized controlled trial undertaken at seven hospitals in China. The primary endpoint was EBV and CMV infections within 3 years post-transplantation. Secondary endpoints included the cumulative incidences of relapse, non-relapse mortality (NRM), overall survival (OS), leukemia-free survival (LFS), and graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) at 3 years.Two hundred two patients were assigned to sorafenib maintenance (n=100) or non-maintenance (control, n=102). Median extended follow-up post-transplantation was 36.8 (range, 2.5-67.1) months. The 3-year cumulative incidences of EBV-DNAemia and EBV-associated diseases were 24.0% (95% CI: 16.1-32.8%) and 5.0% (1.8-10.6%) in the sorafenib group, and 24.5% (16.6-33.2%) and 5.9% (2.4-11.6%) in the control group (P=0.937; P=0.771). The 3-year cumulative incidences of CMV-DNAemia and CMV-associated diseases were 56.0% (45.6-65.1%) and 8.0% (3.7-14.4%) in the sorafenib group, and 52.9% (42.7-62.1%) and 8.8% (4.3-15.3%) in the control group (P=0.997; P=0.826). The 3-year cumulative mortality of EBV- and CMV-associated diseases was 0.0% (0.0-0.0%) and 2.0% (0.4-6.4%) in the sorafenib group, and 1.0% (0.1-4.8%) and 2.0% (0.4-6.3%) in the control group (P=0.322, P=0.980). The 3-year cumulative incidences of relapse, NRM, OS, LFS, and GRFS were 13.0%, 11.1%, 79.0%, 75.9%, and 65.8% in the sorafenib group and 34.8%, 12.7%, 61.4%, 52.5%, and 46.6% in the control group, respectively (P<0.001, P=0.656, P=0.005, P<0.001, P=0.003). The reconstitution of T lymphocyte subsets, B lymphocytes, and natural killer cells was similar between the two groups (all P>0.05).Sorafenib maintenance post-transplantation does not increase the incidence and mortality of EBV and CMV infections, demonstrating a favorable safety profile.ClinicalTrials.gov Identifier: NCT02474290 . Registered on June 14, 2015." @default.
• W4294131894 created "2022-09-02" @default.
• W4294131894 creator A5000828146 @default.
• W4294131894 creator A5010298865 @default.
• W4294131894 creator A5022746945 @default.
• W4294131894 creator A5023708281 @default.
• W4294131894 creator A5023776809 @default.
• W4294131894 creator A5032457247 @default.
• W4294131894 creator A5037029781 @default.
• W4294131894 creator A5037458498 @default.
• W4294131894 creator A5037645443 @default.
• W4294131894 creator A5041183580 @default.
• W4294131894 creator A5044301848 @default.
• W4294131894 creator A5046892926 @default.
• W4294131894 creator A5053447705 @default.
• W4294131894 creator A5059032368 @default.
• W4294131894 creator A5079594267 @default.
• W4294131894 creator A5080036092 @default.
• W4294131894 creator A5080152413 @default.
• W4294131894 creator A5088854472 @default.
• W4294131894 date "2022-09-02" @default.
• W4294131894 modified "2023-10-16" @default.
• W4294131894 title "Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial" @default.
• W4294131894 cites W1986090016 @default.
• W4294131894 cites W1992168621 @default.
• W4294131894 cites W1992677374 @default.
• W4294131894 cites W2007134676 @default.
• W4294131894 cites W2019111335 @default.
• W4294131894 cites W2087595943 @default.
• W4294131894 cites W2158138034 @default.
• W4294131894 cites W2416358021 @default.
• W4294131894 cites W2419140434 @default.
• W4294131894 cites W2465355173 @default.
• W4294131894 cites W2472166008 @default.
• W4294131894 cites W2502940040 @default.
• W4294131894 cites W2606880299 @default.
• W4294131894 cites W2754160328 @default.
• W4294131894 cites W2767914526 @default.
• W4294131894 cites W2788138754 @default.
• W4294131894 cites W2788680157 @default.
• W4294131894 cites W2789864883 @default.
• W4294131894 cites W2793929453 @default.
• W4294131894 cites W2883681290 @default.
• W4294131894 cites W2917772228 @default.
• W4294131894 cites W2936304332 @default.
• W4294131894 cites W2945219383 @default.
• W4294131894 cites W2947447274 @default.
• W4294131894 cites W2965624976 @default.
• W4294131894 cites W2966396806 @default.
• W4294131894 cites W2967100498 @default.
• W4294131894 cites W3000653492 @default.
• W4294131894 cites W3011737407 @default.
• W4294131894 cites W3014928753 @default.
• W4294131894 cites W3028224410 @default.
• W4294131894 cites W3042846071 @default.
• W4294131894 cites W3047808971 @default.
• W4294131894 cites W3091945199 @default.
• W4294131894 cites W3119843276 @default.
• W4294131894 cites W3128929763 @default.
• W4294131894 cites W3138670192 @default.
• W4294131894 cites W3176523174 @default.
• W4294131894 cites W4200527149 @default.
• W4294131894 doi "https://doi.org/10.1186/s12916-022-02479-x" @default.
• W4294131894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36050712" @default.
• W4294131894 hasPublicationYear "2022" @default.
• W4294131894 type Work @default.
• W4294131894 citedByCount "4" @default.
• W4294131894 countsByYear W42941318942023 @default.
• W4294131894 crossrefType "journal-article" @default.
• W4294131894 hasAuthorship W4294131894A5000828146 @default.
• W4294131894 hasAuthorship W4294131894A5010298865 @default.
• W4294131894 hasAuthorship W4294131894A5022746945 @default.
• W4294131894 hasAuthorship W4294131894A5023708281 @default.
• W4294131894 hasAuthorship W4294131894A5023776809 @default.
• W4294131894 hasAuthorship W4294131894A5032457247 @default.
• W4294131894 hasAuthorship W4294131894A5037029781 @default.
• W4294131894 hasAuthorship W4294131894A5037458498 @default.
• W4294131894 hasAuthorship W4294131894A5037645443 @default.
• W4294131894 hasAuthorship W4294131894A5041183580 @default.
• W4294131894 hasAuthorship W4294131894A5044301848 @default.
• W4294131894 hasAuthorship W4294131894A5046892926 @default.
• W4294131894 hasAuthorship W4294131894A5053447705 @default.
• W4294131894 hasAuthorship W4294131894A5059032368 @default.
• W4294131894 hasAuthorship W4294131894A5079594267 @default.
• W4294131894 hasAuthorship W4294131894A5080036092 @default.
• W4294131894 hasAuthorship W4294131894A5080152413 @default.
• W4294131894 hasAuthorship W4294131894A5088854472 @default.
• W4294131894 hasBestOaLocation W42941318941 @default.
• W4294131894 hasConcept C126322002 @default.
• W4294131894 hasConcept C143998085 @default.
• W4294131894 hasConcept C168563851 @default.
• W4294131894 hasConcept C203014093 @default.
• W4294131894 hasConcept C203092338 @default.
• W4294131894 hasConcept C2522874641 @default.
• W4294131894 hasConcept C2776409557 @default.
• W4294131894 hasConcept C2777408962 @default.
• W4294131894 hasConcept C2777732132 @default.
• W4294131894 hasConcept C2778019345 @default.
• W4294131894 hasConcept C2778695046 @default.
• W4294131894 hasConcept C2778729363 @default.

• next